113 related articles for article (PubMed ID: 23847045)
1. Novel conjugation of tumor-necrosis-factor-related apoptosis-inducing ligand (TRAIL) with monomethyl auristatin E for efficient antitumor drug delivery.
Pan LQ; Wang HB; Xie ZM; Li ZH; Tang XJ; Xu YC; Zhang C; Naranmandura H; Chen SQ
Adv Mater; 2013 Sep; 25(34):4718-22. PubMed ID: 23847045
[TBL] [Abstract][Full Text] [Related]
2. Optimizing Multistep Delivery of PEGylated Tumor-Necrosis-Factor-Related Apoptosis-Inducing Ligand-Toxin Conjugates for Improved Antitumor Activities.
Wei X; Yang X; Zhao W; Xu Y; Pan L; Chen S
Bioconjug Chem; 2017 Aug; 28(8):2180-2189. PubMed ID: 28697305
[TBL] [Abstract][Full Text] [Related]
3. Hetero-modification of TRAIL trimer for improved drug delivery and in vivo antitumor activities.
Pan LQ; Zhao WB; Lai J; Ding D; Wei XY; Li YY; Liu WH; Yang XY; Xu YC; Chen SQ
Sci Rep; 2015 Oct; 5():14872. PubMed ID: 26445897
[TBL] [Abstract][Full Text] [Related]
4. Activating Autophagy Enhanced the Antitumor Effect of Antibody Drug Conjugates Rituximab-Monomethyl Auristatin E.
Wang Y; Zhang X; Fan J; Chen W; Luan J; Nan Y; Wang S; Chen Q; Zhang Y; Wu Y; Ju D
Front Immunol; 2018; 9():1799. PubMed ID: 30123222
[TBL] [Abstract][Full Text] [Related]
5. Reductively cleavable polymer-drug conjugates based on dendritic polyglycerol sulfate and monomethyl auristatin E as anticancer drugs.
Rades N; Achazi K; Qiu M; Deng C; Haag R; Zhong Z; Licha K
J Control Release; 2019 Apr; 300():13-21. PubMed ID: 30794827
[TBL] [Abstract][Full Text] [Related]
6. Synergistic anti-cancer effects via co-delivery of TNF-related apoptosis-inducing ligand (TRAIL/Apo2L) and doxorubicin using micellar nanoparticles.
Lee AL; Dhillon SH; Wang Y; Pervaiz S; Fan W; Yang YY
Mol Biosyst; 2011 May; 7(5):1512-22. PubMed ID: 21350763
[TBL] [Abstract][Full Text] [Related]
7. Evaluation of RGD-targeted albumin carriers for specific delivery of auristatin E to tumor blood vessels.
Temming K; Meyer DL; Zabinski R; Dijkers EC; Poelstra K; Molema G; Kok RJ
Bioconjug Chem; 2006; 17(6):1385-94. PubMed ID: 17105215
[TBL] [Abstract][Full Text] [Related]
8. Effects of Recombinant Circularly Permuted Tumor Necrosis Factor (TNF)-Related Apoptosis-Inducing Ligand (TRAIL) (Recombinant Mutant Human TRAIL) in Combination with 5-Fluorouracil in Human Colorectal Cancer Cell Lines HCT116 and SW480.
Sun T; Zhu T; Liang X; Yang S; Zhao R
Med Sci Monit; 2018 Apr; 24():2550-2561. PubMed ID: 29695684
[TBL] [Abstract][Full Text] [Related]
9. Improved antitumor activity of TRAIL fusion protein via formation of self-assembling nanoparticle.
Huang K; Duan N; Zhang C; Mo R; Hua Z
Sci Rep; 2017 Feb; 7():41904. PubMed ID: 28225020
[TBL] [Abstract][Full Text] [Related]
10. Site-specific PEGylation of a mutated-cysteine residue and its effect on tumor necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL).
Pan LQ; Wang HB; Lai J; Xu YC; Zhang C; Chen SQ
Biomaterials; 2013 Dec; 34(36):9115-23. PubMed ID: 23981355
[TBL] [Abstract][Full Text] [Related]
11. Enhancement of antitumor properties of rhTRAIL by affinity increase toward its death receptors.
Reis CR; van der Sloot AM; Szegezdi E; Natoni A; Tur V; Cool RH; Samali A; Serrano L; Quax WJ
Biochemistry; 2009 Mar; 48(10):2180-91. PubMed ID: 19236007
[TBL] [Abstract][Full Text] [Related]
12. Antitumor activity of a novel recombinant mutant human tumor necrosis factor-related apoptosis-inducing ligand.
Fang F; Wang AP; Yang SF
Acta Pharmacol Sin; 2005 Nov; 26(11):1373-81. PubMed ID: 16225761
[TBL] [Abstract][Full Text] [Related]
13. NanoTRAIL-Oncology: A Strategic Approach in Cancer Research and Therapy.
Shi Y; Pang X; Wang J; Liu G
Adv Healthc Mater; 2018 Jun; 7(11):e1800053. PubMed ID: 29527836
[TBL] [Abstract][Full Text] [Related]
14. Sortase A-Generated Highly Potent Anti-CD20-MMAE Conjugates for Efficient Elimination of B-Lineage Lymphomas.
Pan L; Zhao W; Lai J; Ding D; Zhang Q; Yang X; Huang M; Jin S; Xu Y; Zeng S; Chou JJ; Chen S
Small; 2017 Feb; 13(6):. PubMed ID: 27873460
[TBL] [Abstract][Full Text] [Related]
15. A bispecific fusion protein and a bifunctional enediyne-energized fusion protein consisting of TRAIL, EGFR peptide ligand, and apoprotein of lidamycin against EGFR and DR4/5 show potent antitumor activity.
Zhu D; Wang X; Shang Y; Li Y; Jiang W; Li L; Chen SZ
Anticancer Drugs; 2015 Jan; 26(1):64-73. PubMed ID: 25122444
[TBL] [Abstract][Full Text] [Related]
16. A novel TRAIL mutant-TRAIL-Mu3 enhances the antitumor effects by the increased affinity and the up-expression of DR5 in pancreatic cancer.
Huang M; Zhu H; Yi C; Yan J; Wei L; Yang X; Chen S; Huang Y
Cancer Chemother Pharmacol; 2018 Nov; 82(5):829-838. PubMed ID: 30167846
[TBL] [Abstract][Full Text] [Related]
17. Trastuzumab-monomethyl auristatin E conjugate exhibits potent cytotoxic activity in vitro against HER2-positive human breast cancer.
Abdollahpour-Alitappeh M; Lotfinia M; Bagheri N; Sineh Sepehr K; Habibi-Anbouhi M; Kobarfard F; Balalaie S; Foroumadi A; Abbaszadeh-Goudarzi G; Abbaszadeh-Goudarzi K; Abolhassani M
J Cell Physiol; 2019 Mar; 234(3):2693-2704. PubMed ID: 30246298
[TBL] [Abstract][Full Text] [Related]
18. Combination Nanopreparations of a Novel Proapoptotic Drug - NCL-240, TRAIL and siRNA.
Riehle R; Pattni B; Jhaveri A; Kulkarni A; Thakur G; Degterev A; Torchilin V
Pharm Res; 2016 Jul; 33(7):1587-601. PubMed ID: 26951567
[TBL] [Abstract][Full Text] [Related]
19. Characterization of Site-Specifically Conjugated Monomethyl Auristatin E- and Duocarmycin-Based Anti-PSMA Antibody-Drug Conjugates for Treatment of PSMA-Expressing Tumors.
Lütje S; Gerrits D; Molkenboer-Kuenen JD; Herrmann K; Fracasso G; Colombatti M; Boerman OC; Heskamp S
J Nucl Med; 2018 Mar; 59(3):494-501. PubMed ID: 29146698
[TBL] [Abstract][Full Text] [Related]
20. TGF3L fusion enhances the antitumor activity of TRAIL by promoting assembly into polymers.
Wang Y; Lei Q; Yan Z; Shen C; Wang N
Biochem Pharmacol; 2018 Sep; 155():510-523. PubMed ID: 30059675
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
